U.S. Markets open in 2 hrs 6 mins
  • S&P Futures

    4,546.75
    +22.50 (+0.50%)
     
  • Dow Futures

    35,055.00
    +145.00 (+0.42%)
     
  • Nasdaq Futures

    15,167.25
    +133.75 (+0.89%)
     
  • Russell 2000 Futures

    2,069.20
    +10.00 (+0.49%)
     
  • Crude Oil

    86.76
    -0.20 (-0.23%)
     
  • Gold

    1,839.10
    -4.10 (-0.22%)
     
  • Silver

    24.25
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1335
    -0.0012 (-0.1020%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.06
    +0.27 (+1.18%)
     
  • GBP/USD

    1.3603
    -0.0009 (-0.0666%)
     
  • USD/JPY

    114.3170
    -0.0360 (-0.0315%)
     
  • BTC-USD

    42,013.46
    -62.91 (-0.15%)
     
  • CMC Crypto 200

    997.79
    +3.05 (+0.31%)
     
  • FTSE 100

    7,587.49
    -2.17 (-0.03%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com